SLS BIO Statistics

Total Valuation

SLS BIO has a market cap or net worth of KRW 26.89 billion. The enterprise value is 20.82 billion.

Market Cap	26.89B
Enterprise Value	20.82B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

SLS BIO has 13.66 million shares outstanding. The number of shares has increased by 18.73% in one year.

Current Share Class	13.66M
Shares Outstanding	13.66M
Shares Change (YoY)	+18.73%
Shares Change (QoQ)	-0.36%
Owned by Insiders (%)	30.99%
Owned by Institutions (%)	n/a
Float	7.99M

Valuation Ratios

The trailing PE ratio is 8,141.94.

PE Ratio	8,141.94
Forward PE	n/a
PS Ratio	3.33
PB Ratio	2.18
P/TBV Ratio	2.21
P/FCF Ratio	51.74
P/OCF Ratio	15.92
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.71, with an EV/FCF ratio of 40.06.

EV / Earnings	6,304.24
EV / Sales	2.58
EV / EBITDA	15.71
EV / EBIT	n/a
EV / FCF	40.06

Financial Position

The company has a current ratio of 8.05, with a Debt / Equity ratio of 0.13.

Current Ratio	8.05
Quick Ratio	7.85
Debt / Equity	0.13
Debt / EBITDA	1.20
Debt / FCF	3.07
Interest Coverage	-0.14

Financial Efficiency

Return on equity (ROE) is 0.03% and return on invested capital (ROIC) is -0.05%.

Return on Equity (ROE)	0.03%
Return on Assets (ROA)	-0.04%
Return on Invested Capital (ROIC)	-0.05%
Return on Capital Employed (ROCE)	-0.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.48
Inventory Turnover	28.11

Taxes

In the past 12 months, SLS BIO has paid 18.41 million in taxes.

Income Tax	18.41M
Effective Tax Rate	84.79%

Stock Price Statistics

The stock price has decreased by -54.84% in the last 52 weeks. The beta is 0.84, so SLS BIO's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	-54.84%
50-Day Moving Average	1,967.30
200-Day Moving Average	1,959.10
Relative Strength Index (RSI)	48.32
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SLS BIO had revenue of KRW 8.08 billion and earned 3.30 million in profits. Earnings per share was 0.19.

Revenue	8.08B
Gross Profit	1.97B
Operating Income	-11.09M
Pretax Income	21.72M
Net Income	3.30M
EBITDA	1.33B
EBIT	-11.09M
Earnings Per Share (EPS)	0.19

Full Income Statement

Balance Sheet

The company has 7.66 billion in cash and 1.59 billion in debt, giving a net cash position of 6.07 billion or 444.42 per share.

Cash & Cash Equivalents	7.66B
Total Debt	1.59B
Net Cash	6.07B
Net Cash Per Share	444.42
Equity (Book Value)	12.32B
Book Value Per Share	818.90
Working Capital	8.29B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.69 billion and capital expenditures -1.17 billion, giving a free cash flow of 519.72 million.

Operating Cash Flow	1.69B
Capital Expenditures	-1.17B
Free Cash Flow	519.72M
FCF Per Share	38.06

Full Cash Flow Statement

Margins

Gross margin is 24.44%, with operating and profit margins of -0.14% and 0.04%.

Gross Margin	24.44%
Operating Margin	-0.14%
Pretax Margin	0.27%
Profit Margin	0.04%
EBITDA Margin	16.40%
EBIT Margin	-0.14%
FCF Margin	6.43%

Dividends & Yields

SLS BIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	11,618.49%
Buyback Yield	-18.73%
Shareholder Yield	n/a
Earnings Yield	0.01%
FCF Yield	1.93%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on July 12, 2024. It was a forward split with a ratio of 2.

Last Split Date	Jul 12, 2024
Split Type	Forward
Split Ratio	2

Scores

SLS BIO has an Altman Z-Score of 7.62 and a Piotroski F-Score of 4.

Altman Z-Score	7.62
Piotroski F-Score	4